Clinical Genetic Features and Neoadjuvant Chemotherapy Response in HER2-Low Breast Cancers: A Retrospective, Multicenter Cohort Study-Reference-Cited by-同舟云学术

Clinical Genetic Features and Neoadjuvant Chemotherapy Response in HER2-Low Breast Cancers: A Retrospective, Multicenter Cohort Study

Published:2023-03-31 Issue:9 Volume:30 Page:5653-5662
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Yang Libo,Liu Yuqiong,Han DanDan,Fu Sha,Guo Shuangping,Bao Longlong,Shi Yi,Huang Rongfang,Wan Huan,Li Wencai,Wang Zhe,Zhou Xiaoyan,Chen Gang,Liu Yueping,Ye Feng^ORCID

Funder

Interdisciplinary Crossing and Integration of Medicine and Engineering for Talent Training Fund, West China Hospital, Sichuan University

Sichuan Provincial Natural Science Foundation Project

1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-023-13311-y.pdf

Reference32 articles.

1. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update. J Clin Oncol. 2018;36(20):2105–22.

2. Yang L, Chen M, Pu T, et al. The differences of clinicopathologic characteristics among subgroups of reclassified HER2 fluorescence in situ hybridization (FISH) according to the ASCO/CAP 2018 breast cancer HER2 testing guidelines. J Clin Pathol. 2020;73(5):283–90.

3. Hanna WM, Slodkowska E, Lu FI, Nafisi H, Nofech-Mozes S. Comparative analysis of human epidermal growth factor receptor 2 testing in breast cancer according to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline recommendations. J Clin Oncol. 2017;35(26):3039–45.

4. Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22(8):1151–61.

5. Shao Y, Yu Y, Luo Z, et al. Clinical, pathological complete response, and prognosis characteristics of HER2-low breast cancer in the neoadjuvant chemotherapy setting: a retrospective analysis. Ann Surg Oncol. 2022;29(13):8026–34.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant chemotherapy efficacy and prognosis in HER2-low and HER2-zero breast cancer patients by HR status: a retrospective study in China;PeerJ;2024-05-29

2. Comparison of the Pathological Complete Response Rate and Survival Between HER2-Low and HER2-Zero Breast Cancer in Neoadjuvant Chemotherapy Setting: A Systematic Review and Meta-Analysis;Clinical Breast Cancer;2024-05

3. HER2-low breast cancer and response to neoadjuvant chemotherapy: a population-based cohort study;Pathology;2024-04

4. Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy;The Breast;2024-02

5. ASO Author Reflections: Genetic Heterogeneity in HER2-Low Breast Cancers Reflects Different Treatment Responses;Annals of Surgical Oncology;2023-04-10